Comparative Cost and Saving Analysis of Insulin Glargine-300U/mL (Gla-300) vs Insulin Degludec 100 U/mL in the Treatment of Type 2 Diabetes Mellitus Based on the BRIGHT Study

OBJECTIVES: The objective of this study was to conduct a comparative analysis of the long-acting insulin Glargine-300U/mL (Gla-300) vs Insulin Degludec 100 U/mL in the treatment of type 2 diabetes mellitus based on the input of the BRIGHT study, assuming only 2^nd Generation basal insulin is used

METHODS: For this analysis, A budget impact model was used, with a 5-years time horizon for patients with T2DM, epidemiology data references were from National office of statistics, Stepwise WHO and IDMPS wave 7, the eligible population considered was T2DM adults patients, all treated with 2^nd generation BI . the following inputs were extracted from the BRIGHT RCT (Open label active controlled parallel-group trial): demographics (weight) efficacy outcomes (dose), Safety outcomes (glycemic events)

The costs included are treatment costs (price assumptions considered based on local pricing guidelines), direct costs related to management of non-severe hypoglycemia diurnal and nocturnal. All costs were reported in euros. Deterministic sensitivity analysis was carried out on all relevant costs and parameters included in the budget impact assessment

RESULTS: Results showed a negative budget of BI = -12 M € cumulative over the 5 years. The breakdown of the budget impact per cost category is: -9 M € for drug acquisition costs, and -3.1 M € for direct costs of managements of glycemic events . Sensitivity analyses determined that patient weight considered, and the proportion of patient population had the potential to impact the base case analysis

CONCLUSIONS: This analysis of insulin Glargine-300U/mL in Algeria demonstrated the considerable saving on health expenses vs Insulin Degludec. This represents the potential benefit coming from the use of one insulin that demonstrates improvement of glycemic outcomes at lower cost. In conclusion, starting using the Gla-300 for the treatment of T2DM patients would lead to a relevant cost saving and minimizing the burden of diabetes management